Nestle Health Science
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nestle Health Science
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.
The public biotech’s first foray into the microbiome started well, but a clinical trial failure followed by a success has now left Seres with both regulatory and commercial issues.
Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.
- Medical Devices
- OTC, Consumer
- Other Names / Subsidiaries
- Prometheus Laboratories, Inc., Nestle S.A.